Cases
Aratana Therapeutics, Inc. (PETX)
Merger
Overview
Overview
- Date:
- 4/29/2019
- Company Name:
- Aratana Therapeutics, Inc.
- Stock Symbol:
- PETX
- Company Name - Buyer:
- Elanco Animal Health
- Stock Symbol - Buyer:
- ELAN
- Status:
- Closed/Complete
- Merger Announcement Date:
- 4/26/2019
- Court:
- U.S. District Court: District of Delaware
NEW YORK, April 29, 2019 – Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Aratana Therapeutics, Inc. (NASDAQ: PETX) on behalf of stockholders concerning the proposed merger with Elanco Animal Health (NYSE: ELAN).
Pursuant to the proposed transaction, announced on April 26, 2019 and valued at $245 million, Aratana stockholders will receive 0.1481 shares of Elanco for each share of Aratana common stock owned. The investigation focuses on whether Aratana and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company’s stockholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.
If you own Aratana shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 308-1869, or by filling out the contact form below. There is no cost or obligation to you.
Pursuant to the proposed transaction, announced on April 26, 2019 and valued at $245 million, Aratana stockholders will receive 0.1481 shares of Elanco for each share of Aratana common stock owned. The investigation focuses on whether Aratana and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company’s stockholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.
If you own Aratana shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 308-1869, or by filling out the contact form below. There is no cost or obligation to you.